Company intelligence / Profile preview

BioPep

Richmond, British Columbia, Canada

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Pre-clinical pharmacological studies and preliminary CMC specifications completed for BPS-001; pursuing IND from US FDA and CTA from Health Canada for Phase 1/2 trials in metastatic castration-resistant prostate cancer (mCRPC). BPS-001 shows multi-mechanistic activity: inhibits angiogenesis, increases apoptosis, anti-inflammatory.[1][4][5]

Therapeutic areas: OncologyImmunology
Modalities: BiologicPeptides
Industry: Biotech

Beyond the preview

Go deeper on BioPep.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioPep.

Explore the full profile